← Back to Pharmacy
Clinical Pharmacology
Français
Lesson 15

Section 15.1

Principles of Chemotherapy & Safe Handling

Explain why chemotherapy can affect both cancer and healthy fast-growing cells, distinguish patient safety from occupational hazardous-drug control, and apply a protocol-directed response to a possible exposure or infusion problem.

Learn

Idea 1 / 5

Chemotherapy is purposeful, systemic treatment

Chemotherapy uses medicines to kill cancer cells or stop their growth. It may be used to cure a cancer, reduce the chance that it returns, slow its growth, or relieve symptoms. A regimen is selected for a particular cancer, treatment goal, prior therapy and person—not simply because a medicine is called “chemotherapy.” Treatment is commonly organised in cycles with treatment and recovery periods, and it may be combined with surgery, radiation, immunotherapy or other systemic treatment. The oncology team determines the regimen and monitoring plan.

For example

Two people receiving anticancer medicines may have different goals: one regimen can be given after surgery to reduce recurrence risk, while another may be used to control symptoms from advanced disease.

Read all essential notes

Chemotherapy is purposeful, systemic treatment

Chemotherapy uses medicines to kill cancer cells or stop their growth. It may be used to cure a cancer, reduce the chance that it returns, slow its growth, or relieve symptoms. A regimen is selected for a particular cancer, treatment goal, prior therapy and person—not simply because a medicine is called “chemotherapy.” Treatment is commonly organised in cycles with treatment and recovery periods, and it may be combined with surgery, radiation, immunotherapy or other systemic treatment. The oncology team determines the regimen and monitoring plan.

Two people receiving anticancer medicines may have different goals: one regimen can be given after surgery to reduce recurrence risk, while another may be used to control symptoms from advanced disease.

Fast growth explains benefit and many adverse effects

Many cytotoxic medicines exploit the rapid division of cancer cells, but they can also affect healthy tissues whose cells renew quickly, including bone marrow, the digestive lining and hair follicles. This helps explain why low blood-cell counts, infection risk, nausea or vomiting, mouth problems and hair loss can occur. The pattern and timing of adverse effects vary substantially by medicine, combination, dose, route and individual factors. Do not use a calendar rule to predict a person’s lowest blood count: review the prescribed regimen, laboratory trend, symptoms and local oncology pathway.

A fever in a person on chemotherapy is not explained away as an expected side effect. It needs the urgency assessment and escalation specified by the person’s oncology service.

Patient safety and worker safety are related but different

For a patient, safe chemotherapy means confirming the authorised regimen and identity, assessing symptoms and relevant tests, administering through the approved pathway, and responding promptly to unexpected symptoms or an infusion concern. For workers and others who handle a hazardous drug, the aim is to prevent workplace exposure. Exposure can occur during receiving, preparation, administration, cleaning, waste handling, laundering or handling contaminated body waste. A drug’s benefit to a patient does not make routine contact safe for an unprotected worker.

A pharmacist preparing a hazardous drug, a nurse connecting an infusion and an environmental-services worker cleaning a treatment area have different tasks, but all need the facility’s hazardous-drug controls.

Safe handling uses layers of control

Hazardous-drug safety is a system, not a pair of gloves. The hierarchy of controls starts with reducing or eliminating exposure where possible, then uses engineering controls and safe work practices, with personal protective equipment (PPE) as a final barrier. Depending on the task and local risk assessment, this can include designated preparation equipment, closed-system or needleless equipment, chemotherapy-tested gloves, a nonabsorbent closed-front gown with tight cuffs, and splash or respiratory protection when the task creates that hazard. Product information, the current hazardous-drug list and the institution’s policy determine the exact controls.

A closed-system transfer device can reduce the chance of leakage during a task, but it does not replace training, correct PPE, cleaning procedures or reporting a spill.

Stop, protect, contain and escalate unexpected events

Pain, burning, swelling, redness, leakage or loss of expected infusion flow can signal an infusion complication, including possible extravasation. Stop the infusion and immediately use the institution’s extravasation pathway; do not improvise an antidote, compress or restart decision from memory. Similarly, a spill or possible worker exposure is a safety event: keep people away as appropriate, use the facility spill/exposure procedure and report it promptly. The exact actions, PPE and follow-up depend on the drug, route, setting and local protocol.

During an infusion, a patient reports new burning at the access site. The safe learner response is to stop the infusion, protect the patient and summon the approved protocol and responsible clinician—not to flush the line or select a treatment independently.

Common misconception: “Chemotherapy safety means only watching the patient for side effects” is incomplete. Patient assessment is essential, but hazardous-drug controls also protect pharmacy, nursing, environmental-services, laundry and other workers from unintended exposure.

Explore

Interactive teaching plate · 15.1

Chemotherapy: target, renewing tissue, safety systems

Systemic anticancer treatment can affect cancer and healthy renewing cells. Patient monitoring and hazardous-drug control are linked but distinct systems.

Chemotherapy: target, renewing tissue, safety systemsTopic-specific causal schematic. Use the labelled controls to select an explanation.schematic · not to scale
Go deeper: worked example

A nurse is administering an antineoplastic infusion through an approved device. The patient suddenly reports burning and tightness near the access site; the nurse also notices swelling and that the infusion no longer flows as expected.

  1. Recognize a possible infusion complication. Burning, swelling and a changed flow pattern matter together; do not dismiss them as routine chemotherapy discomfort.
  2. Stop the infusion to avoid continuing a possible tissue exposure, keep the access situation available for the authorised assessment, and protect the patient. Do not flush the line or independently select a compress, antidote or restart plan.
  3. Activate the institution’s extravasation pathway and notify the responsible oncology clinician. Identify the drug and document the observed findings and timing according to the local procedure; the protocol supplies the drug-specific treatment and follow-up.
  4. If a leak or contamination also creates a worker-exposure concern, apply the hazardous-drug spill/exposure procedure and task-appropriate controls. Patient treatment response and occupational exposure response are connected, but neither substitutes for the other.

The correct first move is not to remember a universal antidote. It is to stop a concerning infusion and activate the verified, drug-specific local pathway while protecting both the patient and staff.

Explain it yourself

Why is a closed-system transfer device helpful but not enough by itself for hazardous-drug safety?

Reveal explanation

It can reduce leakage or escape during a defined transfer, but exposure can also occur during receiving, preparation, administration, cleaning, waste handling and a spill. Safe handling therefore requires task-specific engineering controls, work practices, PPE, training and reporting—not one device alone.

Create and evaluate

Create a short safety handoff for a planned hazardous-drug administration. Separate: (1) the patient checks and signs that require escalation, (2) the worker-exposure controls for the task, and (3) what to do if an infusion concern or spill occurs. Use only the approved local protocol for drug-specific directions; do not invent doses or antidotes.

Formative activity: compare your reasoning with the rubric. This response is not automatically graded and does not award mastery. It remains only on this page and is cleared when you leave.

Compare with the rubric and example
  • Names regimen/identity verification, relevant symptoms and tests, and unexpected infusion findings that should activate the oncology or extravasation pathway.
  • Explains exposure controls as a hierarchy: designated engineering/work-practice controls plus task-appropriate PPE, with the facility risk assessment and policy setting the details.
  • States that a concerning infusion is stopped and escalated through the verified protocol, and that a spill or possible exposure uses the facility procedure and reporting route.

Before administration, verify the authorised regimen and patient identity and review the symptoms and tests required by the oncology plan; tell the team to escalate fever, new concerning symptoms or pain, swelling, leakage or altered flow at the access site. For the task, use the designated engineering/work-practice controls and the PPE required by the facility’s hazardous-drug assessment. If an infusion becomes concerning, stop it and activate the drug-specific extravasation pathway rather than flushing or improvising treatment; if a spill or possible worker exposure occurs, isolate the area as directed, use the spill/exposure procedure and report it promptly.

Sources and review status

Educational draft. Medical and French-language expert review pending. External sources require an internet connection; essential explanations are included above.

Check my understanding

Mastery Question Gate

Answer all questions correctly to unlock the next lesson. Retakes vary the selection when enough questions are available; some questions may repeat.

1. What clinical concern characterizes the chemotherapy 'nadir' period?